Tandem Diabetes Care traded at $19.48 this Tuesday February 3rd, decreasing $0.61 or 3.04 percent since the previous trading session. Looking back, over the last four weeks, Tandem Diabetes Care lost 15.85 percent. Over the last 12 months, its price fell by 45.87 percent. Looking ahead, we forecast Tandem Diabetes Care to be priced at 19.28 by the end of this quarter and at 17.55 in one year, according to Trading Economics global macro models projections and analysts expectations.
Tandem Diabetes Care, Inc. is a medical device company. The Company is engaged in designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing, sales and support activities principally focus on its flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), and its product offerings. The t:slim X2 is based on its technology platform and is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. Its products also include Basal-IQ technology and Control-IQ technology. The Basal-IQ technology is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. Its Control-IQ technology is a hybrid-closed loop feature, designed to help increase a user's time in targeted glycemic range.